9.79
+0.19
(1.98%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 9.56 - 9.92 |
| 52 week | 5.65 - 11.34 |
| Open | 9.68 |
| Vol / Avg. | 1.30M/908,708.00 |
| Mkt cap | 1.13B |
| P/E | - |
| Div/yield | - |
| EPS | -1.62 |
| Shares | 115.52M |
| Beta | 0.77 |
| Inst. own | 93% |
Events
Aug 5, 2013
Q2 2013 NEKTAR THERAPEUTICS Earnings Release
Jun 13, 2013
NEKTAR THERAPEUTICS Annual Shareholder Meeting
- 5:00PM EDT -
May 21, 2013
NEKTAR THERAPEUTICS at UBS Global Healthcare Conference
- 10:00AM EDT -
May 9, 2013
Q1 2013 NEKTAR THERAPEUTICS Earnings Conference Call
May 6, 2013
Q1 2013 NEKTAR THERAPEUTICS Earnings Release
Mar 5, 2013
NEKTAR THERAPEUTICS at Cowen Health Care Conference
Feb 28, 2013
Q4 2012 NEKTAR THERAPEUTICS Earnings Conference Call
Feb 26, 2013
NEKTAR THERAPEUTICS at TVG BioPartnering North America
Feb 25, 2013
Q4 2012 NEKTAR THERAPEUTICS Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -239.36% | -211.67% |
| Operating margin | -197.37% | -173.91% |
| EBITD margin | - | -153.98% |
| Return on average assets | -46.71% | -31.12% |
| Return on average equity | -994.90% | -140.39% |
| Employees | 433 | - |
| Carbon Disclosure Rating | - | - |
Address
455 Mission Bay Boulevard South
SAN FRANCISCO, CA 94158
United States - Map
+1-415-4825300 (Phone)
+1-415-3395300 (Fax)
SAN FRANCISCO, CA 94158
United States - Map
+1-415-4825300 (Phone)
+1-415-3395300 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Provides a portfolio of drug delivery technologies to assist pharmaceutical and biotechnology companies with the development of their drug products, drug delivery, product franchises, and product pipelines. The Company offers drug delivery technologies that includes molecule engineering, particle engineering, and drug delivery solutions for both large and small molecules.
Officers and directors
| Robert B. Chess | Independent Chairman of the Board | |
| Howard W. Robin | President, Chief Executive Officer, Director | |
| John Nicholson | Chief Financial Officer, Senior Vice President | |
| Jillian B. Thomsen | Senior Vice President - Finance, Chief Accounting Officer | |
| Stephen K. Doberstein Ph.D. | Senior Vice President, Chief Scientific Officer | |
| Gil M. Labrucherie J.D. | Senior Vice President, General Counsel, Secretary | |
| Rinko Ghosh | Senior Vice President, Chief Business Officer | |
| Maninder Hora Ph.D. | Senior Vice President - Pharmaceutical Development and Manufacturing Operations | |
| Robert A. Medve M.D. | Senior Vice President, Chief Medical Officer | |
| R. Scott Greer | Independent Director |